Evotec AG (NASDAQ:EVO – Get Free Report)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $3.03, but opened at $2.92. Evotec shares last traded at $2.90, with a volume of 2,931 shares trading hands.
Analyst Upgrades and Downgrades
Several equities analysts recently weighed in on the company. Berenberg Bank assumed coverage on Evotec in a research note on Tuesday, February 3rd. They issued a “buy” rating for the company. Weiss Ratings upgraded Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. Wall Street Zen lowered Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, HC Wainwright assumed coverage on Evotec in a research note on Wednesday, April 15th. They issued a “buy” rating and a $7.00 price target for the company. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.00.
View Our Latest Stock Report on Evotec
Evotec Stock Performance
Evotec (NASDAQ:EVO – Get Free Report) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%.The company had revenue of $297.02 million for the quarter. As a group, analysts expect that Evotec AG will post -0.63 earnings per share for the current year.
Institutional Investors Weigh In On Evotec
Several institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP boosted its holdings in shares of Evotec by 25.7% during the 4th quarter. Wellington Management Group LLP now owns 1,797,444 shares of the company’s stock worth $5,536,000 after purchasing an additional 367,545 shares during the last quarter. DCF Advisers LLC boosted its holdings in shares of Evotec by 7.6% during the 3rd quarter. DCF Advisers LLC now owns 1,198,993 shares of the company’s stock worth $4,352,000 after purchasing an additional 84,500 shares during the last quarter. WCM Investment Management LLC boosted its holdings in shares of Evotec by 12.1% during the 1st quarter. WCM Investment Management LLC now owns 627,260 shares of the company’s stock worth $1,480,000 after purchasing an additional 67,917 shares during the last quarter. ABC Arbitrage SA boosted its holdings in shares of Evotec by 319.7% during the 4th quarter. ABC Arbitrage SA now owns 554,287 shares of the company’s stock worth $1,707,000 after purchasing an additional 422,230 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Evotec during the 4th quarter worth approximately $565,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.
Evotec Company Profile
Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.
Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.
Featured Articles
- Five stocks we like better than Evotec
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
- 3 Defense Giants Boosting Dividends as Shares Take a Ride
- Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
